On September 24, AKESO fell 3.18% in regular trading to HK$94.45, with turnover of approximately HK$76.39 million. The stock continued its volatile pattern following the release of ivonescimab HARMONi-2 overall survival data at the World Conference on Lung Cancer, having surged over 9% on September 21, retreated 3.07% on September 22, and rebounded 3.39% on September 23.

After concentrated release of positive catalysts — including median OS of 30.8 months versus pembrolizumab's 22.6 months (HR 0.73) and multiple bulge-bracket upgrades from CICC (target HK$130), Jefferies (target HK$226), and Citi (target HK$171) — the stock faces renewed selling pressure as short-term gains are digested ahead of the Mid-Autumn and National Day holidays. The broader biotech sector weakened in tandem, with Remegen down 4.70%, 3SBio down 2.23%, and Innovent Biologics down 2.03%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)